Abstract: Pharmaceutical compositions and methods of using same comprising a non-steroidal anti-inflammatory drug in combination with at least one other active component selected from an antihistamine, decongestant, cough suppressant (antitussive) or expectorant are provided for the relief of cough, cold and cold-like symptoms.

Abstract: Pharmaceutical compositions and methods of using same comprising a non-steroidal anti-inflammatory drug in combination with at least one other active component selected from an antihistamine, decongestant, cough suppressant (antitussive) or expectorant are provided for the relief of cough, cold and cold-like symptoms.

Abstract: Compounds of the Formula I: ##STR1## are inhibitors of the mammalian 5-lipoxygenase enzyme system of the arachidonic acid cascade. As such, these compounds are useful therapeutic agents for treating allergic conditions, asthma, cardiovascular disorders and inflammation.

Abstract: Invention relates to nasal administration of physiologically active therapeutic agents and dosage forms useful for such administration.

Abstract: Pharmaceutical compositions and methods of using same comprising a non-steroidal anti-inflammatory drug in combination with at least one other active component selected from an antihistamine, decongestant, cough suppressant (antitussive) or expectorant are provided for the relief of cough, cold and cold-like symptoms.

Abstract: A method for reducing body fat stores in vertebrate animals by administer a prolactin-inhibitor to the animal in a dose which effects such reduction without a concomitant decrease in body weight is disclosed.

Abstract: Pharmaceutical compositions and methods of using same comprising a non-steroidal anti-inflammatory drug in combination with at least one other active component selected from an antihistamine, decongestant, cough suppressant (antitussive) or expectorant are provided for the relief of cough, cold and coldlike symptoms.

Abstract: The present invention provides (1) a new organogermanium compound of the following general formula: ##STR1## wherein A represents a hydrogen atom, a lower alkyl group such as a methyl or ethyl group or a phenyl group, B represents a hydrogen atom or a lower alkyl group as mentioned above and Z represents a hydroxyl or amino group and (2) an opioid peptide-degrading enzyme inhibitor containing the compound (1) as a principal ingredient.

Abstract: Joint destruction associated with arthritic disease in warm blooded animals is treated with unexpected safety using 3,5-dichloromethotrexate. The therapeutic index therefor is unexpectedly enhanced through combination therapy using a post administration of leucovorin.

Abstract: The present invention relates to the use of secondary 2-aminoalkyl-5-pyridinols of the general formula I ##STR1## wherein R is hydrogen or lower alkyl, m is an integer from 2 to 4 and n is an integer from 1 to 7, and the acid addition salts thereof, as nootropic agents and antidepressants and for the preparation of pharmaceutical compositions having nootropic and antidepressant activity.

Abstract: There is provided a method for alleviating the decrease of psychomotor performances in depressed or tired humans in need of such alleviation which consists in administering to such humans a safe but effective amount of 2,2-bis phenoxy-N,N-dimethyl ethylamine or an acid addition salt thereof.

Abstract: The present invention provides a method of treating anxiety in humans employing a 4-substituted-1,3,4,5-tetrahydrobenz[c,d]indole-6-carboxamide derivative.

Abstract: An anti-arthritic preparation consisting essentially of the anti-inflammatory, nonsteroidal agents aspirin and phenylbutazone, the anti-inflammatory corticosteroid prednisone, and the skeletal muscle relaxant methocarbamol. The use of calcium carbonate and vitamin D as adjuncts is contemplated in protecting against osteoporosis and possible replacement of bone tissue.

Abstract: A topically and systemically administered anti-inflammatory composition for human and for veterinary consumption which comprises compounds of the general formula: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are defined hydrocarbon attachments and Y is --OH or a phenolic ester group derived from the reaction of such --OH group with a carboxylic acid halide or anhydride.In typical compounds covered by said general formula(a) R.sub.1 is H, R.sub.2 is 5,n-octanoyl, Y is hydroxy and R.sub.3 is p-trifluoromethylphenyl;(b) R.sub.1 is H, R.sub.2 is 5,n-decanoyl, Y is hydroxy and R.sub.3 is benzothiazol-2-yl and(c) R.sub.1 is H, R.sub.2 is 5,n-decanoyl, Y is acryloyloxy and R.sub.3 is p-nitrophenyl.

Abstract: A method is disclosed for lowering rheumatoid factor blood levels by administering an effective amount of etodolac.

Abstract: Carnitine, which preferentially accumulates in cardiac and skeletal muscle, is coupled to a protease inhibitor, or any other pharmaceutically active compound for the purpose of site-specific drug delivery to these tissues.These products may be useful in a variety of muscle wasting diseases. They may also be useful in a variety of cardiac conditions including those produced by cardiac ischemia. They may also be useful as growth promoters for animals.

Abstract: Method of sensitizing hypoxic tumor cells to radiotherapy and chemotherapy by contacting the cells or the vasculature thereof with an aqueous dispersion of an oxygen carrying perfluoro compound and a dispersant for the compound, and sensitizing chemotherapeutic and protective compositions therefor.

Abstract: Phenyl-3-aminoalkyl-4-methyl-2,6-dioxopiperidines of the Formula I ##STR1## wherein: R.sub.1 represents methoxy, ethoxy or hydroxy,R.sub.2 represents methoxy, ethoxy, hydroxy or hydrogen;each R.sub.3 independently represents methyl or ethyl;R.sub.4 represents hydrogen or methyl;R.sub.5 represents hydrogen or methyl; andn represents 2 or 3,and a pharmacologically acceptable acid addition salt thereof (a) have anxiolytic activity, (b) antagonize the anxiogenic activity of benzodiazepine inverse agonists, (c) reduce chronic abnormally high brain levels of serotonin or its metabolite 5-hydroxy-indoleacetic acid and (d) have antibacterial and antiviral activity. These activities are believed to be related to a reduction in serotonin turnover caused by blocking the depolarization activation of tryptophan hydroxylase. Novel compositions comprise the compounds with a benzodiazepine agonist or benzodiazepine inverse agonist.

Abstract: Sleep disorders in mammals, such as insomnia and narcolepsy, are treated by administering an effective amount of ethyl 4-acetoxybutanoate, or a closely related homolog thereof. The compounds may also be administered to mammals to cause muscle relaxation and as animal anaesthetics. Moreover the compounds appear to inhibit the release of dopamine in the brain, and are hence useful also in treatment of conditions which are associated with abnormalities of dopamine release and dopamine sensitivities, such as Parkinson's disease, schizophrenia and tardive dyskenesia.

Abstract: Novel topical creams or lotions containing 2,6-di-t-butyl-4-(2'-thenoyl)phenol exhibiting good skin penetrability are disclosed.